

Erratum to: Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Robert S. Rosenson¹ · Terry A. Jacobson² · David Preiss³ · Stephen C. Djedjos⁴ · Ricardo Dent⁵ · Ian Bridges⁶ · Michael Miller⁷

Published online: 6 August 2016
© Springer Science+Business Media New York 2016

Erratum to: *Cardiovasc Drugs Ther* (2016) 30:305-313
DOI 10.1007/s10557-016-6666-1

The original version of this article unfortunately contained a mistake. In the Results of the Abstract section, where it says "...compared to -6 % vs. placebo and -39 % vs. ezetimibe..." it should read "...compared to -65 % vs. placebo and -39 % vs. ezetimibe ...".

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10557-016-6666-1>.

✉ Robert S. Rosenson
robert.rosenson@mssm.edu

- ¹ Mount Sinai Heart, Cardiometabolics Unit, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave, MC1 Level, New York, NY 10029, USA
- ² Emory University, 201 Dowman Drive, Atlanta, GA 30322, USA
- ³ Clinical Trial Service Unit and Epidemiological Studies Unit, Oxford University, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, UK
- ⁴ Amgen Inc., One Amgen Center Dr, Thousand Oaks, CA 91320, USA
- ⁵ Amgen (Europe) GmbH, Dammstrasse 23, 6300 Zug, Switzerland
- ⁶ Amgen Ltd, 240 Cambridge Science Park, Milton, Cambridge CB4 0WD, UK
- ⁷ University of Maryland School of Medicine, 655 W Baltimore St, Baltimore, MD 21201, USA